Prodrugs for nasal drug delivery.
Recently, the delivery of xenobiotics via the nasal route has received increasing attention as this offers several advantages, i.e. high systemic availability, rapid onset of action. Both charged and uncharged forms of drugs can be transported across the nasal epithelium. This mucosa is rich in various metabolizing enzymes such as aldehyde dehydrogenase, glutathione transferases, epoxide hydrolases, cyt-P450-dependent monooxygenases. The presence of these enzymes may make it possible for pharmaceutical scientists to design prodrugs for better absorption and high systemic availability. Recent advances in peptide nasal delivery through prodrug modification has been thoroughly discussed in this paper. Finally, nasally delivered therapeutic agents targeted to various disease states have been examined.